| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Apatinib for chemotherapy-refractory extensive-stage SCLC: a retrospective study
|
Li, Hui
|
|
2019
|
83 |
6 |
p. 1083-1090
|
artikel
|
| 2 |
A phase I study of gemcitabine + dasatinib (gd) or gemcitabine + dasatinib + cetuximab (GDC) in refractory solid tumors
|
Mettu, Niharika B.
|
|
2019
|
83 |
6 |
p. 1025-1035
|
artikel
|
| 3 |
Clinically relevant concentrations of lidocaine inhibit tumor angiogenesis through suppressing VEGF/VEGFR2 signaling
|
Gao, Jin
|
|
2019
|
83 |
6 |
p. 1007-1015
|
artikel
|
| 4 |
Comparison of palonosetron and granisetron in triplet antiemetic therapy in nonmetastatic breast cancer patients receiving high emetogenic chemotherapy: a multicenter, prospective, and observational study
|
Araz, Murat
|
|
2019
|
83 |
6 |
p. 1091-1097
|
artikel
|
| 5 |
Comparison of two different carboplatin and weekly paclitaxel schedule in elderly advanced non-small cell lung cancer patients
|
Kıvrak Salim, Derya
|
|
2019
|
83 |
6 |
p. 1137-1145
|
artikel
|
| 6 |
De-escalated neoadjuvant therapy with nanoparticle albumin-bound paclitaxel and trastuzumab for low-risk pure HER2 breast cancer
|
Tanaka, Satoru
|
|
2019
|
83 |
6 |
p. 1099-1104
|
artikel
|
| 7 |
d,l-Methadone does not improve radio- and chemotherapy in glioblastoma in vitro
|
Oppermann, Henry
|
|
2019
|
83 |
6 |
p. 1017-1024
|
artikel
|
| 8 |
Docetaxel, cisplatin, and 5-fluorouracil combination chemoradiotherapy for patients with cervical esophageal cancer: a single-center retrospective study
|
Sakai, Makoto
|
|
2019
|
83 |
6 |
p. 1121-1126
|
artikel
|
| 9 |
Equipotent doses of daunorubicin and idarubicin for AML: a meta-analysis of clinical trials versus in vitro estimation
|
Adige, Sunil
|
|
2019
|
83 |
6 |
p. 1105-1112
|
artikel
|
| 10 |
First-in-human study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-CD27L antibody-drug conjugate AMG 172 in patients with relapsed/refractory renal cell carcinoma
|
Massard, Christophe
|
|
2019
|
83 |
6 |
p. 1057-1063
|
artikel
|
| 11 |
FLAG vs FLAG-IDA: outcomes in relapsed/refractory acute leukemias
|
Farooq, Muhammad Umer
|
|
2019
|
83 |
6 |
p. 1191-1193
|
artikel
|
| 12 |
Inactivation of apaziquone by haematuria: implications for the design of phase III clinical trials against non-muscle invasive bladder cancer
|
Phillips, Roger M.
|
|
2019
|
83 |
6 |
p. 1183-1189
|
artikel
|
| 13 |
Investigation of anti-tumor effect of doxorubicin-loaded human serum albumin nanoparticles prepared by a desolvation technique
|
Kimura, Kotaro
|
|
2019
|
83 |
6 |
p. 1113-1120
|
artikel
|
| 14 |
LncRNA SNHG16 sponges miR-98-5p to regulate cellular processes in osteosarcoma
|
Liao, Shian
|
|
2019
|
83 |
6 |
p. 1065-1074
|
artikel
|
| 15 |
Modeling long-term tumor growth and kill after combinations of radiation and radiosensitizing agents
|
Cardilin, Tim
|
|
2019
|
83 |
6 |
p. 1159-1173
|
artikel
|
| 16 |
Outcomes of preoperative S-1 and docetaxel combination chemotherapy in patients with locally advanced gastric cancer
|
Kosaka, Takashi
|
|
2019
|
83 |
6 |
p. 1047-1055
|
artikel
|
| 17 |
Pharmacokinetic and exploratory exposure–response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study
|
Kirschbrown, Whitney P.
|
|
2019
|
83 |
6 |
p. 1147-1158
|
artikel
|
| 18 |
Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial
|
Rivera, Fernando
|
|
2019
|
83 |
6 |
p. 1175-1181
|
artikel
|
| 19 |
Placental growth factor is a predictive biomarker for ramucirumab treatment in advanced gastric cancer
|
Natsume, Makoto
|
|
2019
|
83 |
6 |
p. 1037-1046
|
artikel
|
| 20 |
Rabeprazole intake does not affect systemic exposure to capecitabine and its metabolites, 5′-deoxy-5-fluorocytidine, 5′-deoxy-5-fluorouridine, and 5-fluorouracil
|
Sekido, Masae
|
|
2019
|
83 |
6 |
p. 1127-1135
|
artikel
|
| 21 |
Short-time use of crizotinib as neoadjuvant in ALK-positive non-small cell lung carcinoma can be a chance for resectability
|
Kilickap, Saadettin
|
|
2019
|
83 |
6 |
p. 1195-1196
|
artikel
|
| 22 |
The combination of olaratumab with gemcitabine and docetaxel arrests a chemotherapy-resistant undifferentiated soft-tissue sarcoma in a patient-derived orthotopic xenograft mouse model
|
Higuchi, Takashi
|
|
2019
|
83 |
6 |
p. 1075-1082
|
artikel
|
Tijdschrift beschrijving